It turns out just about everything is RIGHT with Onyx: Right market: cancer, Right product: BAY 43-9006, small molecule growth inhibitor, Right trials: Phase III Fast Track, 2 Phase II, 8 Phase I, Right financials: strong cash position, diminishing losses, Right management: a group of been-there/done-that folks, Right market support: analysts upgrading stock
